Journal Article10.1016/J.SEMCANCER.2020.03.016
Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature
Chakrabhavi Dhananjaya Mohan,Shobith Rangappa,Habbanakuppe D. Preetham,S. Chandra Nayaka,Vijai Kumar Gupta,Salundi Basappa,Gautam Sethi,Kanchugarakoppal S. Rangappa +7 more
124
TL;DR: This review has provided a comprehensive overview of mechanisms of STAT3 signal transduction and its endogenous negative modulators, the role ofSTAT3 in oncogenesis, the interplay of miRNAs in STAT3 signaling, and mechanisms involved in persistent activation of stat3.
read more
About: This article is published in Seminars in Cancer Biology. The article was published on 20 Apr 2020. The article focuses on the topics: STAT3 & Stat3 Signaling Pathway.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The JAK/STAT signaling pathway: from bench to clinic.
TL;DR: In this article, the authors discuss the current knowledge about the composition, activation, and regulation of the JAK/STAT pathway and highlight the role of the pathway and its inhibitors in various diseases.
1.2K
Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy.
Milad Ashrafizadeh,Masoud Delfi,Farid Hashemi,Amirhossein Zabolian,Hossein Saleki,Morteza Bagherian,Negar Azami,Mahdi Vasheghani Farahani,Seyed Omid Sharifzadeh,Soodeh Hamzehlou,Kiavash Hushmandi,Pooyan Makvandi,Ali Zarrabi,Michael R. Hamblin,Rajender S. Varma +14 more
TL;DR: In this paper, the potential of chitosan-based nanoparticles for the delivery of siRNA in cancer therapy is discussed; proliferation, metastasis and chemoresistance are suppressed by siRNA-loaded CS nanoparticles.
133
Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer Immunotherapy
Yunchen Yang,Jia Huang,Min Liu,Yige Qiu,Qiaohui Chen,Tianjiao Zhao,Zuoxiu Xiao,Yuqi Yang,Yitian Jiang,Qiong Huang,Kelong Ai +10 more
TL;DR: Wang et al. as mentioned in this paper summarized the characteristics of the tumor immune microenvironment and the mechanisms of ICD, and the representative advances of SDT-based nanomedicines for cancer immunotherapy.
123
Diosgenin, a steroidal saponin, and its analogs: Effective therapies against different chronic diseases.
Dey Parama,Monikongkona Boruah,Kumari Yachna,Varsha Rana,Kishore Banik,Choudhary Harsha,Krishan Kumar Thakur,Uma Dutta,Aditya Arya,Xinliang Mao,Kwang Seok Ahn,Ajaikumar B. Kunnumakkara +11 more
TL;DR: The review summarises the efficacy of diosgenin and its analogues for developing as a potent drug against several chronic diseases.
116
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy.
Manoj Garg,Muthu K. Shanmugam,Vipul Bhardwaj,Akul Goel,Rajat Gupta,Arundhiti Sharma,Prakash Baligar,Alan Prem Kumar,Boon Cher Goh,Boon Cher Goh,Lingzhi Wang,Gautam Sethi +11 more
TL;DR: This review has discussed the classical regulation of STAT3 via diverse growth factors, cytokines, G‐protein‐coupled receptors, as well as toll‐like receptors, and the potential role of noncoding RNAs in regulating STAT3 signaling.
115
References
Inflammation and cancer
Lisa M. Coussens,Zena Werb +1 more
TL;DR: It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration.
14.4K
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Natural Products as Sources of New Drugs over the Last 25 Years
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of two prior reviews that were published in this journal in 1997 and 2003 and is able to identify only one de novo combinatorial compound approved as a drug in this 25 plus year time frame.
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
David J. Newman,Gordon M. Cragg +1 more
TL;DR: This review is an updated and expanded version of the three prior reviews and adds a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations.
STATs in cancer inflammation and immunity: a leading role for STAT3
TL;DR: Signal transducer and activator of transcription proteins are central in determining whether immune responses in the tumour microenvironment promote or inhibit cancer, and STAT3 is a promising target to redirect inflammation for cancer therapy.